Compare Organon & Co. Common Stock (OGN) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Tesla, Inc. — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Tesla, Inc. trades at $362.35 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 408.8× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Tesla, Inc. for 88 Days on average.
| OGN | TSLA | |
|---|---|---|
Market Cap | $3.62B | $1.48T |
Volume | 2,892,999 | 18,314,332 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $489.88 |
52-Week Low | $5.70 | $298.16 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $11.04B | $1.45T |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Tesla (TSLA) trades at $367.16, down 2.88% on the day, amid mixed signals. The technical outlook is bullish based on moving averages, but oscillators are neutral. Recent earnings showed a Q2 2026 miss after two prior beats. Revenue declined slightly in 2025 to $94.83B, with net income margin compressing to 4%. The company maintains a strong balance sheet with $36.56B in cash, though valuation ratios like a P/E of 347.44 remain elevated. News highlights focus on autonomous driving approvals in Europe and a potential cheaper EV model.
Tesla's investment case balances high growth expectations in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $441.36 implies upside, but investors face risks from competitive pressures, volatile earnings, and the stock's sensitivity to sentiment shifts around its AI and robotics initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
